Xspray Pharma AB: 2 directors
Two Directors at Xspray Pharma AB bought 216,052 shares at between 45.735SEK and 49.979SEK. The significance rating of the trade was 65/100.Is that information sufficient for you to make an investment decision?
This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following.
Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules.
The names of board members along with their holdings are detailed together with some company fundamentals for the last three years where available. In addition, Directors Deals scores each Director according to the performance of their past trades. This tells you which Directors are the most successful at picking the time to buy and sell shares. In addition to director 'Scoring' data, we give each trade a star rating according to the significance of the trade. The star rating is derived from a statistical value which accounts for a number of factors which are weighted according to our analysis of past trades. These two statistical measures are a proven means of establishing which trades and which directors are worth taking into account when analysing director trading as a guide to future share performance.
As a specialist provider of investment grade financial data, Directors Deals does not issue stock recommendations but aims to contextualise and present data so that investors can draw their own conclusions from director trading activity. Directors Deals Ltd does not accept any responsibility for losses incurred through investment decisions made as a result of these reports.
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
Research suggests that directors know their companies better than the market. For many investors it is intuitive that following the trading patterns of directors and other company insiders can lead to successful investing. They often have detailed knowledge about their companies and generally know when the shares are incorrectly valued. However, that is not always true and with large numbers of trades reported every day on exchanges around the world, it is difficult to know which to follow.
SmartInsider provides valuable insight by supplementing and analysing reported transactions to achieve real insight with a focus on identifying the ‘Smart Insiders’ and highlighting the stand-out transactions they make. Our proven track-record and thirty year pedigree are backed by more recent statistical analysis of historical data.
Our service offers director dealing reports, company reports and monthly summaries with a fully interactive website for further research. We can also provide quant feeds and customised alerts to suit every need at the frequency preferred. SmartInsider covers all markets with a regulatory requirement to report insider activity, over 60,000 companies across 55 markets.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.